Azura Ophthalmics develops first-in-class ophthalmic keratolytics to treat meibomian gland dysfunction (MGD) and other ocular surface diseases. By utilizing the unique properties of keratolytics, the company targets the root causes of these conditions, addressing significant unmet patient needs in ocular health.
Funding
Funding not disclosed
BBFounders
Product
Problem
Meibomian gland dysfunction (MGD) and related ocular surface diseases lack effective treatments that target the underlying causes, leaving a significant unmet need for patients. Current therapies often provide only temporary relief of symptoms without addressing the root of the problem.
Solution
Azura Ophthalmics is developing first-in-class ophthalmic keratolytics designed to treat MGD and other ocular surface diseases by targeting the root causes of these conditions. Their approach combines ophthalmologic and dermatologic solutions to harness the unique properties of keratolytics. This aims to provide a highly differentiated treatment option that addresses the full spectrum of unmet patient needs in lid margin and ocular surface diseases.
Target Audience
The primary target audience includes patients suffering from meibomian gland dysfunction (MGD) and other ocular surface diseases, as well as ophthalmologists and other eye care professionals treating these conditions.
Features
- Utilizes ophthalmic keratolytics to target the root causes of MGD.
- Combines ophthalmologic and dermatologic solutions.
- Aims to provide a differentiated treatment option for ocular surface diseases.